Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study

Amiodarone is a class III antiarrhythmic medication used to treat atrial and ventricular tachyarrhythmias. Pulmonary fibrosis from amiodarone use is a well-documented side effect. Pre-COVID-19 pandemic studies have shown that amiodarone-induced pulmonary fibrosis occurs in 1%-5% of patients and usua...

Descripción completa

Detalles Bibliográficos
Autores principales: Money, David B, Lee, Dae Hyun, Hadar, Ari, Doherty, Justin, Malanga, Christopher, Serino, Alexa, Cohen, Adam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946893/
https://www.ncbi.nlm.nih.gov/pubmed/36843772
http://dx.doi.org/10.7759/cureus.34109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946893/
https://www.ncbi.nlm.nih.gov/pubmed/36843772
http://dx.doi.org/10.7759/cureus.34109

Ejemplares similares